With TUKYSA, More Time is Possible
TUKYSA 
/too-KYE-sah/, along with HERCEPTIN® (trastuzumab) and XELODA® (capecitabine) offers another chance at treating HER2+ metastatic breast cancer.
In a clinical study, TUKYSA*:
- Offered more time without cancer growing and spreading (median time without progression was 7.8 months with TUKYSA* vs 5.6 months with trastuzumab and capecitabine alone)
- Helped people live longer (median overall survival was 21.9 months with TUKYSA* vs 17.4 months with trastuzumab and capecitabine alone)
Median: The middle number in a group of numbers arranged from lowest to highest; also called the midpoint.
*TUKYSA is part of a treatment plan that includes trastuzumab and capecitabine.
Possible Side Effects
As with all cancer treatments, side effects are possible.
The most common side effects included diarrhea; rash, redness, pain, swelling, or blisters on the palms of your hands or soles of your feet; nausea; and tiredness. These are not all the possible side effects of TUKYSA, and you may also get side effects from the other medicines taken with TUKYSA.
Here’s what you can expect from treatment
Another Chance at Treating Your Cancer
TUKYSA, along with trastuzumab and capecitabine, is a targeted oral treatment option. It's for people with HER2+ metastatic breast cancer who have received at least 1 other treatment in the metastatic setting, such as trastuzumab, PERJETA® (pertuzumab), or KADCYLA® (trastuzumab emtansine).
Learn about the TUKYSA clinical study
Select Safety Information
Select Safety Information
What are the possible side effects of TUKYSA?
TUKYSA may cause serious side effects, including:
TUKYSA may cause serious side effects, including:
- Diarrhea (watery, loose, or frequent stools) is common and can sometimes be severe. Tell your healthcare provider if you have a change in your bowel movements or severe diarrhea. Severe diarrhea can cause a loss of too much body fluid (dehydration), low blood pressure, kidney problems, and death. Your healthcare provider may prescribe medicines to treat your diarrhea during treatment with TUKYSA.
- Liver Problems, including severe cases. Your healthcare provider will test your blood to check your liver function before starting and every 3 weeks during treatment with TUKYSA, or as needed. Tell your healthcare provider right away if you have any signs and symptoms of liver problems including itching, yellowing of the skin or eyes, dark or brown urine (tea-colored), pain or discomfort in the right upper stomach area (abdomen), feeling very tired, decreased appetite, or bleeding or bruising more easily than normal.
Ready to Learn More About TUKYSA?
Get answers to frequently asked questions about treatment
Our Thanks and Gratitude
Seagen would like to extend our sincere gratitude and deepest appreciation to the people living with HER2+ metastatic breast cancer and their families for:
- Participating in the clinical studies that enabled TUKYSA to be approved by the US Food and Drug Administration (FDA)
- Speaking about their experience and sharing their everyday hopes
Share Your Experience with TUKYSA
Your story can help educate, encourage, and inspire others.
